Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 4;12:7111–7121. doi: 10.2147/OTT.S219623

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Feng et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

PAM treatment induced the activation of TLR4 signaling in BMDMs. (A) The expression of the TLR family proteins in BMDMs treated with PAM. (B) The expression of the TLR4 signal pathway proteins in BMDMs treated with PAM. (C) The expression of indicated cytokines in WT BMDMs treated with PAM without or in combination with the TLR4 inhibitor, TAK-242 (1 μM TAK-242). (D) The expression of indicated cytokines in WT or TLR4 KO BMDMs treated with PAM. (E) The migration rate of WT BMDMs treated with TAK-242 (1 μM) with or without PAM co-treatment (left), WT and TLR4 KO BMDMs treated with PAM (right). N=3 for each experiment. **p<0.01.